血管内时代德国胸主动脉瘤修复术发生率上升:德国全国DRG微数据的二次数据分析
该研究分析德国联邦统计局2005至2014年DRG数据,纳入48,098例胸降主动脉瘤病例,其中4,969例(10.3%)接受手术。破裂胸降主动脉瘤中开放修复死亡率为42.9%、胸主动脉腔内修复为22.3%;非破裂病例分别为10.5%与3.7%。腔内治疗与较低死亡率相关(RR 0.31),作者认为对破裂高风险且适合手术者可考虑择期腔内修复。
要点
- 接受手术的胸降主动脉瘤患者中约80%接受腔内治疗
- 破裂、高龄和高合并症评分与更高死亡率显著相关
- 医院手术量并非院内死亡率的显著相关因素
核心结论
- 约80%接受手术治疗的胸降主动脉瘤患者接受腔内治疗,非破裂病例围手术期死亡率较低。
- 作者认为,对破裂高风险且适合手术的个体可考虑择期腔内修复。
- 开放修复、高龄和高合并症评分与更高死亡率相关。
研究设计与样本
- 德国联邦统计局全国DRG数据的二次分析,纳入2005至2014年所有接受胸主动脉腔内修复(TEVAR)或开放主动脉修复(OAR)的破裂(I71.1)或非破裂(I71.2)胸降主动脉瘤住院病例。
- 共识别48,098例胸降主动脉瘤病例,平均年龄69±12岁,65.2%为男性。
- 采用校正性别、年龄、医疗风险(Elixhauser合并症评分)、手术方式和入院类型的多水平多变量回归模型(稳健误差方差)。
- 主要结局为院内死亡率,次要结局为器官并发症,并进行手术量与结局分析。
主要发现
- 4,969例(10.3%)接受手术治疗,其中TEVAR 4,057例(81.6%)、OAR 912例(18.4%)。
- 破裂胸降主动脉瘤死亡率:OAR 42.9% vs TEVAR 22.3%;非破裂胸降主动脉瘤死亡率:OAR 10.5% vs TEVAR 3.7%。
关键数值与推荐
- 破裂胸降主动脉瘤死亡率:OAR 42.9% vs TEVAR 22.3%;非破裂胸降主动脉瘤死亡率:OAR 10.5% vs TEVAR 3.7%。
临床怎么用
- 作者认为,对破裂高风险且适合手术的个体可考虑择期腔内修复。
- 作者指出,接受手术治疗的胸降主动脉瘤患者中约80%接受腔内治疗,非破裂病例围手术期死亡率较低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Nationwide population based data on epidemiology and surgical treatment of descending thoracic aortic (DTA) aneurysms are not available for Germany. The aim was to assess the in hospital incidence, and to report outcomes of patients who received surgical treatment. METHODS: Data were acquired by analysing the diagnosis related group (DRG) statistics of the German Federal Statistical Office. All inpatient cases of ruptured (rDTA aneurysm, ICD Code I71.1) or non-ruptured DTA aneurysm (nrDTA aneurysm; I71.2) who received thoracic endovascular (TEVAR; OPS procedure code 5-38a.7/70/8/80) or open aortic repair (OAR; OPS 5-384.3) between 2005 and 2014 were included. To adjust for sex, age, medical risk (Elixhauser comorbidity score), type of procedure, and type of admission, a multilevel multivariable regression model with robust error variance was applied. The primary outcome was in hospital mortality; secondary outcomes were organ complications. A volume outcome analysis was performed. RESULTS: A total of 48,098 cases of DTA aneurysm (5,848, 12.2% rDTA aneurysm) were identified. The average age was 69 ± 12 years. 65.2% were male. Frequent comorbidities were hypertension (74.9%), peripheral artery disease (including abdominal aortic aneurysm, 42.6%), other heart diseases (41.6%), coronary heart disease (26.2%), and renal failure (22.5%). Surgical treatment was received by 4969 patients (10.3%): 4057 TEVAR (81.6%) and 912 OAR (18.4%) procedures. Mortality for rDTA aneurysm was 42.9% (OAR) and 22.3% (TEVAR). It was 10.5% and 3.7% for DTA aneurysm, respectively. Rupture, increasing age, and higher comorbidity score were significantly associated with higher mortality (RR 6.66, 5.33-8.25; 1.28, 1.17-1.40; and 1.06, 1.05-1.08, respectively). Endovascular treatment was associated with lower mortality (RR 0.31, 0.23-0.41). Hospital volume was not significantly associated with in hospital mortality. CONCLUSIONS: Eighty per cent of patients treated surgically for a DTA aneurysm receive endovascular therapy, with low peri-operative mortality in non-ruptured cases. Elective endovascular repair should be considered for individuals at a high risk of rupture who are fit for surgery. Open repair, increased age, and a high comorbidity score are associated with higher mortality.
引用
- Geisbüsch S, Kuehnl A, Salvermoser M, et al. Increasing Incidence of Thoracic Aortic Aneurysm Repair in Germany in the Endovascular Era: Secondary Data Analysis of the Nationwide German DRG Microdata. Eur J Vasc Endovasc Surg. 2018. PMID: 30220527. doi:10.1016/j.ejvs.2018.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。